ArticleBMC cardiovascular disorders2026
Inequalities in the provision of guideline-directed medical therapy following myocardial infarction: a cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundFollowing myocardial infarction (MI), therapies are recommended that reduce risk and prevent future cardiovascular events. Trends in the provision of guideline-directed medical therapies by sex, age, ethnicity and socioeconomic deprivation status may help identify opportunities to reduce inequalities in post-MI care.
methodsThis cohort study using linked routine healthcare data included patients with MI in South-East Scotland (1 April 2009 to 31st of July 2021). Multivariable logistic regression models with a generalized estimating equation approach were used to assess the association between each sociodemographic factor and the provision of three guideline-directed medical therapies (anti-platelet or anti-thrombotic agent, lipid-lowering therapy and renin-angiotensin system blocker) at 3-, 12-, and 18-months post-discharge. Multivariable cause-specific Cox proportional hazard models were used to evaluate medication status and risk of a composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death across sociodemographic subgroups.
resultsThe study population comprised 7,926 patients (35% female, mean age 65 [SD 13] years). At 3 months, 5,393 (68%) patients were receiving all three guideline-directed medical therapies. Women (adjusted odds ratio at 3 months [aOR 0.69, 95% confidence interval 0.62 to 0.77]) and patients < 50 years (aOR 0.77, 95% confidence interval 0.65 to 0.89) and > 70 years (aOR 0.58, 95% confidence interval 0.51 to 0.65) were less likely to be receiving all three guideline-directed medical therapies at 3 months with similar observations at 12 and 18 months. No differences were observed by ethnicity and socioeconomic groups across the three time points. Patients receiving all three or one/two guideline-directed medical therapies had a lower risk of future cardiovascular events compared to those not receiving any, with this effect being consistent across all subgroups and time points.
conclusionWomen, and both younger and older patients are less likely to be receiving guideline-directed medical therapy following MI, despite its benefit in reducing future cardiovascular events. Targeted strategies to increase provision of secondary prevention in these groups are needed to reduce inequalities and improve post-MI care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.